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Abstract: The aim of the present study was to study the associations between urine albumin excretion,
and a large number of urinary chemokines, cytokines, and growth factors in a normal population. We
selected 90 urine samples from individuals without CVD, diabetes, stroke or kidney disease belonging
to the Prospective Investigation of the Vasculature in Uppsala Seniors Study (41 males and 49 females,
all aged 75 years). Urinary cytokine levels were analyzed with two multiplex assays (proximity
extension assays) and the cytokine levels were correlated with urine albumin. After adjustment for
sex, body mass index (BMI), estimated glomerular filtration rate (eGFR), smoking and multiplicity
testing, 11 biomarkers remained significantly associated with urine albumin: thrombospondin 2,
interleukin 6, interleukin 8, hepatocyte growth factor, matrix metalloproteinase-12 (MMP-12), C-X-C
motif chemokine 9, tumor necrosis factor receptor superfamily member 11B, osteoprotegerin, growth-
regulated alpha protein, C-X-C motif chemokine 6, oncostatin-M (OSM) and fatty acid-binding
protein, intestinal, despite large differences in molecular weights. In this study, we found associations
between urinary albumin and both small and large urine proteins. Additional studies are warranted
to identify cytokine patterns and potential progression markers in various renal diseases.
Keywords: glomerular injury; urine; thrombospondin 2; interleukin 6; interleukin 8; hepatocyte
growth factor
1. Introduction
The measurements of urinary albumin/total protein excretion play key roles in the
detection and classification of renal disease [1]. Even small amounts of albumin, i.e.,
microalbuminuria, are associated with increased morbidity and mortality and are therefore
part of the chronic kidney disease staging according to the Kidney Disease: Improving
Global Out- comes (KIDGO) guidelines [2].
Water and small molecules can freely pass through the glomerular filter. For larger
molecules, the permeability is depending on the size. Under normal conditions the glomeru-
lar membrane is almost impermeable to albumin due to the size and charge of albumin [3,4].
The reference method for albuminuria is the measurement of albumin in a 24-h urine
collection. Twenty-four-hour collections are burdensome for patients to perform and
subject to errors resulting from erroneous collection periods or incomplete collections.
Thus, the 24-h collections have usually been replaced by spot urine samples collected in the
morning or second void. The amounts of albumin in spot samples are usually expressed as
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mg/L or creatinine adjusted as mg albumin/g creatinine. The creatinine adjustments are
used to correct for urine dilutions.
Considering the importance of albuminuria for morbidity and mortality [5], we
wanted to investigate the associations between albuminuria and urine cytokine levels.
Albuminuria is a marker for glomerular damage and tissue damage is associated with
inflammatory response. Thus, it seems likely that albuminuria could be associated with
urinary inflammatory cytokine levels especially if there are active inflammatory processes.
In the present study, we focused on study subjects with relatively normal glomerular filtra-
tion rates (GFR) to minimize the effects of prerenal accumulation of cytokines secondary to
reduced GFR.
The aim of the present study was to study the associations between glomerular
damage, defined as urine albumin excretion, and a large number of urinary chemokines,
cytokines, and growth factors in a cohort of elderly individuals without CVD, diabetes
or stroke. We used a combination of two multiplex proximity extension assays (PEAs) to
detect more than 150 chemokines, cytokines, and growth factors in the urine samples.
2. Materials and Methods
2.1. Patients and Methods
The study subjects were part of the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study cohort [6]. The subjects were chosen from persons living in
the community of Uppsala, Sweden. The urine samples for this study were collected at
the age of 75 years. All participants were medically examined and given a questionnaire
regarding their medical history, lifestyle, including smoking and exercise habits [7]. A
total of 90 individuals without CVD, diabetes, or stroke were included. The samples were
stored at <−70C prior to the analysis. The study was conducted in accordance with the
Declaration of Helsinki. All participants in the study provided written informed consent,
and the Ethics Committee of Uppsala University approved the study protocol.
2.2. Urine Albumin and Creatinine Determinations
Urine albumin was measured using particle enhanced immunological reagents from
Abbott Laboratories (Abbott Park, IL, USA) on an Architect Ci8200 analyzer (Abbot Labo-
ratories, Abbott Park, IL, USA). Urinary creatinine was analyzed with an IDMS-calibrated
modified kinetic Jaffe reaction also on the Architect Ci8200 analyzer (Abbott Laboratories,
Abbott Park, IL, USA). A urine albumin of >20 mg/L or a urine albumin/creatinine ratio
of >2.5 mg/mmol is suggestive of microalbuminuria.
2.3. Determination of Urinary Chemokines, Cytokines, and Growth Factors
The urinary chemokines, cytokines, and growth factors were analyzed using Proseek
Multiplex Cardiovascular II and Inflammation I panels (Olink Bioscience, Uppsala, Swe-
den). The two panels were analyzed in separate plates [8,9]. Briefly, 1 µL urine diluted 1:4
in saline was mixed with 3 µL incubation mix containing paired antibodies labeled with
unique corresponding DNA oligonucleotides. The mixture was first incubated overnight
at 8 ◦C. Then, 96 µL extension mix containing PEA enzyme and PCR reagents was added,
and the samples were incubated for 5 min at room temperature before the plate was trans-
ferred to a thermal cycler for 17 cycles of DNA amplification. A 96.96 Dynamic Array
IFC (Fluidigm, South San Francisco, CA, USA) was prepared and primed according to
the manufacturer’s instructions. In a separate plate, 2.8 µL of sample mixture was mixed
with 7.2 µL detection mix from which 5 µL was loaded into the right side of the primed
96.96 Dynamic Array IFC. The unique primer pairs for each cytokine were loaded into the
left side of the 96.96 Dynamic Array IFC, and the protein expression program was run in
Fluidigm Biomark reader according to the instructions for Proseek. Each of the Proseek
panels analyzed 92 biomarkers, a total of 194 biomarkers.
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2.4. Statistics
Cytokine values above or below the highest and lowest standard points were assigned
the values of these points. Protein levels were measured on a log2-scale and further
transformed to an SD-scale in order to be easily comparable. Linear regression analysis
was applied to relate each urinary protein (dependent variable) vs. urinary albumin
(independent variable). Each urinary protein was evaluated in a separate model. Urinary
creatinine, sex (age same in all subjects), BMI, current smoking and eGFR were used
as confounders in all models (additional independent variables). All the continuous
independent variables, except BMI, were ln-transformed. Analyzing a large number of
relationships increases the risk of false positive findings. The p-values were therefore
adjusted for multiplicity using the false discovery rate (FDR) approach with 0.05 as the
limit [10]. STATA 16 (Stata Inc, College Station, TX, USA) was used for the calculations.
3. Results
3.1. Study Cohort
The cohort consisted of 41 males and 49 females. The basic characteristics of the
study cohort are presented in Table 1. Of the investigated cytokines only intestinal fatty
acid-binding protein with a molecular weight of 15 kDa (p = 0.000028) and Cystatin D with
a molecular weight of 16.1 kDa (p = 0.0004713) were significantly associated with eGFR
according to linear regression.
Table 1. Basic characteristics of the population (n = 90). eGFR = estimated glomerular filtration rate.





Body mass index (BMI) 26.9 3.79
eGFRcombo (mL/min/1.73 m2) 70.3 12.4
Urine albumin (mg/L) 16.5 28.2
3.2. Significant Associations between Urine Cytokines and Urine Albumin
After adjustment for sex, urinary creatinine, eGFR, BMI, smoking, exercise habits
and multiplicity testing, 11 biomarkers remained significantly associated with urine al-
bumin (thrombospondin 2, interleukin 6, interleukin 8, hepatocyte growth factor, matrix
metalloproteinase-12 (MMP-12), C-X-C motif chemokine 9, tumor necrosis factor receptor
superfamily member 11B, osteoprotegerin, growth-regulated alpha protein, C-X-C motif
chemokine 6, oncostatin-M (OSM) and fatty acid-binding protein, intestinal) (Table 2).
3.3. The Influence of Molecular Weights on the Associations between Urine CYtokines and
Urine Albumin
The molecular weights of the cytokines, showing significant associations with urine
albumin excretion, varied between 10.2 and 130 kDa which includes proteins above and
below the glomerular threshold for filtration of proteins. According to Spearman Rank
correlation there were no clear influences of the molecular weight on the associations
between urine cytokines and urine albumin.
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Table 2. Relationships between 79 urinary proteins and urinary albumin adjusted for sex, urinary creatinine, estimated
glomerular filtration rate (eGFR), body mass index (BMI), smoking and exercise habits. Protein levels were measured on a
log2-scale and transformed to a standard deviation (SD)-scale. The results are presented as Beta value, low (Cilow) and
high (Cihigh) confidence intervals, p-values. FDR significance is given for each level of adjustment. The order is sorted on
p-value. For comparison the molecular weight for each biomarker is presented in the right-hand column.
Adjustment for Sex, Urinary Creatinine, eGFR, BMI, Smoking and Exercise Habits
Variable Beta Cilow Cihigh p-Value MW (kDa)
Thrombospondin 2 0.66253 0.43343 0.89163 2.47 × 10−7 * 130
Interleukin 6 0.56538 0.36327 0.76749 5.26 × 10−7 * 23.7
Interleukin 8 0.4989 0.27203 0.72578 0.0000483 * 11.1
Hepatocyte growth factor 0.32414 0.16972 0.47856 0.0000976 * 83.1
Matrix metalloproteinase-12 (MMP-12) 0.51085 0.26328 0.75841 0.0001248 * 54
C-X-C motif chemokine 9 0.399 0.19804 0.59995 0.0002121 * 14
Osteoprotegerin 0.38552 0.17953 0.5915 0.0004508 * 46
Growth-regulated alpha protein 0.40438 0.18537 0.6234 0.0005307 * 11.3
C-X-C motif chemokine 6 0.39919 0.1622 0.63618 0.0014672 * 11.9
Oncostatin-M (OSM) 0.3936 0.1494 0.6378 0.0022716 * 28.5
Fatty acid-binding protein, intestinal 0.35665 0.13527 0.57804 0.002282 * 15.2
Protein S100-A12 (EN-RAGE) 0.36311 0.10689 0.61933 0.0068934 * 10.6
Spondin-2 (SPON2) 0.19605 0.05334 0.33877 0.008721 35.8
Polymeric immunoglobulin receptor (PIgR) 0.2687 0.06465 0.47276 0.011777 83.3
Proheparin-binding EGF-like growth factor
(HB-EGF) −0.30206 −0.56596 −0.03816 0.027785 23.7
Heme oxygenase 1 (HO-1) 0.21941 0.02154 0.41729 0.032871 32.8
C-C motif chemokine 4 (CCL4) 0.25296 0.02471 0.48122 0.032964 10.2
Latency-associated peptide transforming growth
factor beta-1 (LAP TGF-beta-1) 0.28651 0.01783 0.5552 0.03996 44.3
Matrix metalloproteinase-7 (MMP-7) 0.22505 0.01171 0.43839 0.042082 29.7
Dickkopf-related protein 1 (Dkk-1) 0.24117 0.01231 0.47003 0.042289 28.7
Stem cell factor (SCF) 0.23776 0.00863 0.4669 0.045463 30.9
Urokinase-type plasminogen activator (uPA) 0.23353 0.00506 0.462 0.0487 48.5
Monocyte chemotactic protein 1 (MCP-1) 0.15326 −0.00317 0.30969 0.058581 11
Decorin (DCN) −0.1959 −0.40101 0.00921 0.065049 39.7
Tissue factor (TF) 0.20699 −0.01075 0.42474 0.066297 33.1
Prolargin (PRELP) 0.16354 −0.01059 0.33766 0.069549 43.8
Delta and Notch-like epidermal growth
factor-related receptor (DNER) 0.0687 −0.00519 0.14259 0.072327 78.5
Tumor necrosis factor (Ligand) superfamily.
member 12 (TWEAK) 0.24865 −0.01961 0.5169 0.073198 27.2
Programmed cell death 1 ligand 2 (PD-L2) 0.19334 −0.02281 0.40949 0.083611 31
Kidney Injury Molecule (KIM1) 0.14807 −0.02614 0.32228 0.099858 38.7
Proteinase-activated receptor 1 (PAR-1) −0.17143 −0.38624 0.04338 0.121937 47.4
V-set and immunoglobulin domain-containing
protein 2 (VSIG2) 0.17382 −0.04422 0.39186 0.122328 34.3
Leukemia inhibitory factor (LIF) 0.18743 −0.06395 0.43881 0.14804 22
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Table 2. Cont.
Adjustment for Sex, Urinary Creatinine, eGFR, BMI, Smoking and Exercise Habits
Variable Beta Cilow Cihigh p-Value MW (kDa)
Tumor necrosis factor receptor superfamily member
9 (TNFRSF9) 0.15277 −0.05275 0.35829 0.149244 27.9
Protein AMBP (AMBP) 0.17428 −0.0668 0.41537 0.160594 39
T cell surface glycoprotein CD6 isoform (CD6) 0.13314 −0.05205 0.31833 0.162884 71.8
Heat shock 27 kDa protein (HSP 27) 0.15679 −0.06131 0.37488 0.162911 22.8
Fractalkine (CX3CL1) 0.08507 −0.0437 0.21385 0.199288 42.2
TNF-related apoptosis-inducing ligand receptor 2
(TRAIL-R2) 0.11637 −0.06322 0.29597 0.207955 47.9
CD40 ligand (CD40-L) 0.06835 −0.0419 0.1786 0.228085 29.3
CUB domain-containing protein 1 (CDCP1) 0.1487 −0.10124 0.39864 0.247213 92.9
Angiotensin-converting enzyme 2 (ACE2) 0.10271 −0.08248 0.2879 0.280465 92.5
Monocyte chemotactic protein 2 (MCP-2) 0.11316 −0.10873 0.33505 0.320708 11.2
Lipoprotein lipase (LPL) 0.12793 −0.13163 0.38749 0.337081 53.2
Tumor necrosis factor receptor superfamily member
10A (TNFRSF10A) 0.1034 −0.10735 0.31416 0.339281 50.1
Vascular endothelial growth factor A (VEGF-A) 0.10938 −0.11773 0.33648 0.348193 27
Prostasin (PRSS8) 0.11391 −0.12454 0.35237 0.352084 42.8
Interleukin-1 alpha (IL-1 alpha) 0.09469 −0.10705 0.29644 0.360489 30.6
Interleukin-17D (IL-17D) −0.12737 −0.40046 0.14572 0.363538 21.9
Osteoclast-associated immunoglobulin-like receptor
(hOSCAR) −0.09501 −0.30164 0.11162 0.370336 30.5
Natural killer cell receptor 2B4 (CD244) −0.106 −0.34078 0.12878 0.378981 41.6
Interleukin-18 (IL-18) 0.1087 −0.14085 0.35824 0.395949 22.3
T-cell surface glycoprotein CD5 (CD5) 0.07028 −0.0947 0.23525 0.406376 54.6
Interleukin-1 receptor antagonist protein (IL-1ra) 0.07691 −0.10753 0.26136 0.416301 20.1
Lactoylglutathione lyase (GLO1) 0.10629 −0.14975 0.36233 0.418381 20.8
Serine protease 27 (PRSS27) 0.09235 −0.14179 0.32649 0.44188 31.9
SLAM family member 5 (CD84) 0.07309 −0.12097 0.26715 0.462668 38.8
Interleukin-10 receptor subunit beta (IL-10RB) −0.0726 −0.26956 0.12435 0.472201 37
Leukemia inhibitory factor receptor (LIF-R) 0.07275 −0.13932 0.28483 0.503391 123.7
Gastric intrinsic factor (GIF) 0.08151 −0.1627 0.32572 0.514985 45.4
Programmed cell death 1 ligand 1 (PD-L1) 0.04702 −0.09406 0.18811 0.51555 33.3
Galectin-9 (Gal-9) −0.08683 −0.36148 0.18782 0.537352 39.5
Agouti-related protein (AGRP) −0.05759 −0.24091 0.12574 0.539954 14.4
Cathepsin L1 (CTSL1) −0.05031 −0.23928 0.13867 0.603348 37.6
Interleukin-1 receptor-like 2 (IL1RL2) −0.03832 −0.18251 0.10587 0.603952 65.4
Adrenomedullin (ADM) −0.04061 −0.21214 0.13092 0.643965 20.4
P-selectin glycoprotein ligand 1 (PSGL-1) −0.03572 −0.19221 0.12078 0.655922 43.2
Lectin-like oxidized LDL receptor 1 (LOX-1) 0.05033 −0.17039 0.27105 0.656208 31
Carcinoembryonic antigen-related cell adhesion
molecule 8 (CEACAM8) 0.03157 −0.11478 0.17792 0.673617 38.2
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Table 2. Cont.
Adjustment for Sex, Urinary Creatinine, eGFR, BMI, Smoking and Exercise Habits
Variable Beta Cilow Cihigh p-Value MW (kDa)
Transforming growth factor alpha (TGF-alpha) 0.05621 −0.20611 0.31854 0.675672 17
Alpha-L-iduronidase (IDUA) −0.04533 −0.29791 0.20724 0.725979 72.7
Chymotrypsin C (CTRC) −0.04294 −0.2859 0.20002 0.730005 29.5
Cystatin D (CST5) −0.03128 −0.22667 0.16411 0.75455 16.1
Tumor necrosis factor receptor superfamily member
11A (TNFRSF11A) 0.02307 −0.13903 0.18517 0.781033 66
Interleukin-18 receptor 1 (IL-18R1) 0.01487 −0.11934 0.14908 0.828691 62.3
Placenta growth factor (PGF) 0.01696 −0.1476 0.18152 0.840446 24.8
Thrombomodulin (TM) 0.00998 −0.10482 0.12479 0.865108 60.3
Receptor for advanced glycosylation end products
(RAGE) −0.01822 −0.23653 0.2001 0.870512 42.8
Fms-related tyrosine kinase 3 ligand (Flt3L) 0.01844 −0.2344 0.27129 0.886689 26.4
* = Significant after adjustment for multiplicity testing using the false discovery rate (FDR).
4. Discussion
The study subjects were recruited from a community living cohort without any prior
diagnosed kidney injury or compromised eGFR. We showed that there were strong as-
sociations between the urine albumin measured in mg/L and several urinary cytokines,
chemokines, and growth factors. The study subjects were elderly individuals, probably
suffering from some degree of age-related renal dysfunction, including (to some extent)
nephrosclerosis. However, they do not report any specific renal disease. Being an elderly
group of individuals, they are representative of a normal population that most frequently
seek health care.
The main role of kidney glomeruli is to retain large macromolecules while allowing the
transfer of small waste products into the urine. The glomerular filter is a size- and charge-
selective barrier that allows very low amounts of albumin (molecular weight 67 kDa) to be
transferred into the urine. Proteins with molecular weights below approximately 35 kDa
are not retained by the glomeruli but are freely filtered into the primary urine. Theoretically,
an increase in urine albumin caused by glomerular damage should be associated with
an increase in other large plasma proteins. In this study, we found associations between
urine albumin concentrations and both small and large urine proteins. The increases are
thus not caused by a strict increased leakage of large plasma proteins. This indicates that
several of the proteins may be produced locally in the kidney. This is further supported
by the limited number of biomarkers that were significantly associated with eGFR and by
previous publications showing the direct roles of the significantly associated markers in
kidney diseases.
Albuminuria is not only used as a marker of renal dysfunctions but it is also a well-
recognized predictor of cardiovascular risk in both community-based populations and
high-risk populations. In several studies, proinflammatory cytokines have been shown to
be cardiovascular risk markers. Acute or chronic injury to the kidneys or heart is known to
be able to induce acute or chronic dysfunction of the other organ. These interactions are
often referred to as the cardiorenal syndrome. The mechanisms behind these interactions
are poorly understood but could be mediated by cytokines. The aim of this study was
exploratory to investigate if any of these markers do appear in urine from apparently
healthy people. The results indicate that the urine cytokine levels were not due to filtration
in the glomeruli.
Thrombospondin-2 has been shown to act as a regulator of inflammation and matrix
remodeling in experimental kidney disease and thrombospondin-2 gene therapy worsened
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the nephropathy [11]. Interleukin 6 [12] and CXCL1 [13] have been suggested to be involved
in the progression of renal injury in IgA nephritis, while IL-8 levels were associated with
poor prognosis in idiopathic membranous nephropathy [14]. Human HGF treatment
of normal rats caused proteinuria [15]. Both MMP-12 [16] and C-X-C motif chemokine
9 [17] have been shown to contribute to glomerular injury in anti-glomerular basement
membrane glomerulonephritis. Oncostatin-M participated in immune regulation and lack
of oncostatin-M resulted in increased levels of anti-dsDNA and glomerulonephritis [18].
Urinary levels of Osteoprotegerin were positively associated with renal involvement
in lupus nephritis patients [19]. Intestinal fatty acid-binding protein has been reported to be
a promising biomarker for diabetic nephropathy [20]. Thus, the urine biomarkers that we
found to be associated with the glomerular injury marker urine albumin have previously
been reported to be associated with different types of kidney injury and diseases. The
study subjects were recruited from a community living cohort without any prior diagnosed
kidney injury or compromised eGFR. Apparently healthy people do excrete multiple
biomarkers captured with this proteomics platform, in addition to albumin. These results
may serve as a reference when studying patients with specific renal diseases.
Some limitations of the study should be noted, such as targeting a normal population
consisting of 75-year-old individuals who may have a certain degree of nephrosclerosis
and a slightly reduced renal function. Urinary albumin is not a pure and exclusive marker
of increased glomerular permeability, since some albumin is filtered in glomeruli and
subsequently reabsorbed in the proximal tubule.
The determination of broad urine cytokine panels is a new concept and there are
therefore no internationally accepted calibrators for most of the studied biomarkers and
no well-established reference values. The lack of international calibrators means that each
company has to develop their own calibrations which makes it difficult to compare results
obtained with assays from different manufacturers.
In conclusion, the associations in this study were present in a normal population and
could be used as comparator in future studies in specific kidney diseases. Further studies
are warranted to investigate if the differential urine patterns could be identified in various
kidney diseases and if any of these cytokines or cytokine patterns could be used to predict
progression of renal dysfunction or response to treatment in renal disease.
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